reported that PI3K/AKT pathway activation is associated with chemotherapeutic resistance in SCLC [35], indicating that PI3K/AKT pathway suppression might be the main reason why MDK inhibition enhanced the efficacy of CDDP in this study. The gene discussed is AKT1; the disease is small cell lung carcinoma.